Zailyn Tamayo
Manager, ITCards
About
Research
Publications
2026
QuNex recipes: Executable, human-readable workflows for reproducible neuroimaging research
Demšar J, Kraljič A, Matkovič A, Brege S, Pan L, Tamayo Z, Fonteneau C, Helmer M, Ji J, Anticevic A, Korponay C, Salavrakos M, Drucker D, Glasser M, Nickerson L, Cho Y, Repovš G. QuNex recipes: Executable, human-readable workflows for reproducible neuroimaging research. Imaging Neuroscience 2026, 4: imag.a.1274. PMID: 42312086, PMCID: PMC13271150, DOI: 10.1162/imag.a.1274.Peer-Reviewed Original ResearchSeamless integrationHuman-readable formatEnd-to-endOpen-source platformMultiple software toolsWorkflow specificationDataset characteristicsAnalysis of neuroimaging dataData onboardExternal toolsSoftware toolsCustom scriptsParameter settingsPreprocessingWorkflowRecipe filesNeuroimaging communityNeuroimaging analysisFramework7. Distinct Circuits Are Associated With Attenuated Delusions and Hallucinations in Clinical High Risk for Psychosis
Vin R, Fonteneau C, Tamayo Z, Cho Y, Investigators A, Scheinost D, Woods S, Powers A. 7. Distinct Circuits Are Associated With Attenuated Delusions and Hallucinations in Clinical High Risk for Psychosis. Biological Psychiatry 2026, 99: s77-s78. DOI: 10.1016/j.biopsych.2026.03.187.Peer-Reviewed Original Research164. Striatal Connectivity Correlates of Cognitive-Motivational Phenotypes in Pre-Adolescent Children
Brege S, Chen Y, Lin C, Okolo J, Pan L, Pham P, Tamayo Z, JI L, Cho Y. 164. Striatal Connectivity Correlates of Cognitive-Motivational Phenotypes in Pre-Adolescent Children. Biological Psychiatry 2026, 99: s169. DOI: 10.1016/j.biopsych.2026.03.398.Peer-Reviewed Original Research706. Motivation Enhances the Fidelity of Neural Representations of Spatial Working Memory
Rahmati M, Purg N, Schleifer C, Santamauro N, Adkinson B, Kolobaric A, Flynn M, Tamayo Z, Anticevic A, Repovs G, Cho Y. 706. Motivation Enhances the Fidelity of Neural Representations of Spatial Working Memory. Biological Psychiatry 2026, 99: s401. DOI: 10.1016/j.biopsych.2026.03.940.Peer-Reviewed Original ResearchA common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns – CORRIGENDUM
Berkovitch L, Lee K, Ji J, Helmer M, Rahmati M, Demsar J, Kraljic A, Matkovic A, Tamayo Z, Murray J, Repovs G, Krystal J, Martin W, Fonteneau C, Anticevic A. A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns – CORRIGENDUM. Psychological Medicine 2026, 56: e118. PMID: 42037509, PMCID: PMC13125926, DOI: 10.1017/s003329172610422x.Peer-Reviewed Original Research
2025
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam A, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray D, Grinband J, Gur R, Haubold N, Heffernan Z, Heneks M, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro N, Schutte C, Selloni A, Van Snellenberg J, Surti T, Wolf D, Zharyy C, Group T, Abi-Dargham A, Gur R, Lieberman J, Kantrowitz J, Anticevic A, Cho Y, Krystal J. A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trial. Journal Of Psychiatric Research 2025, 194: 196-210. PMID: 41519104, PMCID: PMC13138834, DOI: 10.1016/j.jpsychires.2025.12.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPartial agonistCognitive impairmentSpatial working memoryDouble-blind doseWorking memoryD1/D5 receptorsFunctional neuroimagingNeural mechanismsSchizophreniaTranslational neuroscienceCognitive paradigmNeural circuitsUntreated symptomsD1RDecades of researchFMRIClinical trialsMicro-circuitryNeuroscienceAgonistsImpairmentStudy designD1/D5Clinical dataNeuroimagingCollecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative
Bilgrami Z, Castro E, Agurto C, Liebenthal E, Ennis M, Baker J, Scott I, Colton B, Cho K, Li L, Tamayo Z, Henecks M, Rahimi Eichi H, Henry T, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Cornblatt B, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Diaz-Caneja C, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Yassin W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, McGorry P, Kahn R, Kane J, Anticevic A, Bearden C, Dwyer D, Billah T, Bouix S, Pasternak O, Shenton M, Woods S, Nelson B, Cecchi G, Corcoran C, Wolff P. Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative. Schizophrenia 2025, 11: 125. PMID: 41093845, PMCID: PMC12528486, DOI: 10.1038/s41537-025-00669-z.Peer-Reviewed Original ResearchClinical high riskSample taskEarly psychosisClinical high-risk participantsFacial expressionsCommunity controlsSpeech-based detectionDetection of psychosisPsychosis riskReferential languagePsychosisSyntactic embeddingElicitation conditionsNatural language processing parserEveryday speechSpeech acousticsInterviewer trainingMachine-learning classifiersSpeechLanguage modelElevated useComputational linguisticsTaskData integrationLanguageA common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns
Berkovitch L, Lee K, Ji J, Helmer M, Rahmati M, Demsar J, Kraljic A, Matkovic A, Tamayo Z, Murray J, Repovs G, Krystal J, Martin W, Fonteneau C, Anticevic A. A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns. Psychological Medicine 2025, 55: e185. PMID: 40611472, PMCID: PMC12270277, DOI: 10.1017/s0033291725100962.Peer-Reviewed Original ResearchConceptsMechanisms of Major depressive disordersGlobal brain connectivitySymptom improvementClinical Global Impression ScaleGlobal Impression ScaleMajor depressive disorderManic-like symptomsMeasures of clinical improvementAntidepressant treatmentImpression ScaleDepressive disorderNeural profilesMood improvementSuicidal ideasPattern of clinical improvementSymptom ScaleClinical scalesNeural patternsSertralineBrain connectivityNeural circuitsIndividual itemsPatients' scoresClinical improvementImproved scoresThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Wigman J, Ching A, Chung Y, Eichi H, Lane E, Langholm C, Vaidyam A, Byun A, Haidar A, Hartmann J, Nunez A, Dwyer D, Nasarudin A, Borders O, Scott I, Tamayo Z, Matneja P, Cho K, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Yassin W, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Wolff P, Rowland L, D’Alfonso S, Pasternak O, Bouix S, McGorry P, Kahn R, Kane J, Bearden C, Woods S, Shenton M, Nelson B, Baker J, Torous J. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 83. PMID: 40461469, PMCID: PMC12134270, DOI: 10.1038/s41537-025-00599-w.Peer-Reviewed Original ResearchDigital componentsDigital health technologiesSmartphone-based digital phenotypingNovel digital health technologiesClinical high riskDigital phenotypingDigital dataHealth technologiesPredictive of transition to psychosisReal-life experiencesSchizophrenia ProgramDaily lifeTransition to psychosisPassive dataEpisode of psychosisPsychosis transitionMapping of experiencesTechnologyHigh riskMeta-analytic studiesCollaborative project
Clinical Trials
Current Trials
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
IRB ID2000023688RoleSub InvestigatorPrimary Completion Date07/31/2024Recruiting ParticipantsGenderBothAge18 years - 65 years